Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2014 - 2026)

Lexicon Pharmaceuticals (LXRX) has 13 years of Amortization of Deferred Charges data on file, last reported at $681000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 69.83% year-over-year to $681000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 14.52% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, down 7.86% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $681000.0, up from $495000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for LXRX reached as high as $681000.0 in Q1 2026 and fell as low as $25000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $396529.4 across 5 years, with a median of $402000.0 in 2024.
• Across the five-year window, Amortization of Deferred Charges soared 4212.5% in 2022 and slumped 35.11% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $345000.0 in 2022, then jumped by 79.13% to $618000.0 in 2023, then slumped by 35.11% to $401000.0 in 2024, then increased by 23.44% to $495000.0 in 2025, then jumped by 37.58% to $681000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $681000.0 in Q1 2026, $495000.0 in Q4 2025, and $402000.0 in Q3 2025.